Proteomic analysis of human reproductive fluids

Kοlialexi, Aggeliki; Mavrou, Ariadni; Tsangaris, George Th.

doi:10.1002/prca.200700040

Cited by 8 publications

(7 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Profiling of biological fluids has successfully identified relevant protein biomarkers that can potentially change the early diagnosis and treatment of several medical conditions. 12–14 Two-dimensional (2-D) gel electrophoresis (2-DE) and tandem mass spectrometry (MS–MS) are the most common techniques used in prenatal screening. Both techniques have been used to develop several potential biomarkers in amniotic fluid (AF) and maternal blood.…”

Section: Introductionmentioning

confidence: 99%

Preliminary proteomic-based identification of a novel protein for Down's syndrome in maternal serum

Zhang

Wang

et al. 2012

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Prenatal screening for Down's syndrome (DS) is in need of improvement. As a powerful platform, proteomics techniques could also be used for identification of new biomarkers for DS screening. In this case-control proteome study, pregnant women were diagnosed prenatally by karyotype analysis from amniotic fluid (AF). Maternal serum samples were collected from six pregnancies with fetuses affected by DS and six pregnancies with normal fetuses. First, we used two-dimensional electrophoresis and mass spectrometry to identify the different levels of expression of proteins in maternal serum between the DS and control groups in the second trimester. Second, we used bioinformatics to analyze the proteins by DAVID. Then, the interesting candidates were further tested by enzyme-linked immunosorbent assay (ELISA). Twenty-nine proteins were successfully identified in maternal serum obtained from pregnancies with fetuses affected by DS. The top five proteins up-regulated were serotransferrin (TF), alpha-1b-glycoprotein (A1BG), desmin (DES), alpha-1-antitrypsin (SERPINA1) and ceruloplasmin (CP), while serum amyloid P-component (APCS) was the most down-regulated protein. These 29 proteins were categorized based on binding, catalytic activity and enzyme regulator activity. The biological roles were involved in biological regulation, metabolic processes, cellular processes and response to a stimulus. Based on ELISA, the median concentrations of CP and complement factor B (CFB) were 332.3 and 412.3 ng/mL, respectively. The concentrations of CP and CFB were significantly higher in the DS group than in the control group (P < 0.05). In conclusion, proteomic approaches offer the possibility of further improving the performance of DS screening and our identification of up- and down-regulated proteins may lead to new candidates for DS screening.

show abstract

Section: Introductionmentioning

confidence: 99%

Preliminary proteomic-based identification of a novel protein for Down's syndrome in maternal serum

Zhang

Wang

et al. 2012

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…Proteome analysis based on mass spectrometry (MS) seems to be a promising tool for the identification of disease-related biomarkers. In the field of reproduction, the attention of several researchers has focussed on the examination of the global protein expression in different reproductive fluids in order to provide better diagnosis for foetal chromosomal abnormalities and pregnancy-related complications (Bahtiyar et al, 2007 andKolialexi et al, 2007). Tsangaris et al (2006) applied MS/MS-based proteomics for the identification of proteins differentially expressed in AF samples coming from pregnancies with DS foetuses and chromosomally normal ones.…”

Section: Introductionmentioning

confidence: 99%

Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma

Kοlialexi¹,

Tsangaris

Παπαντωνίου

et al. 2008

Prenatal Diagnosis

Self Cite

View full text Add to dashboard Cite

Background Despite the large impact of ultrasonographic and biochemical markers on prenatal screening, the ability to accurately diagnose Down syndrome (DS) is still limited and better diagnostic testing is needed.Methods Plasma from 8 women carrying a DS foetus and 12 with non-DS foetuses matched for gestational age, maternal age and ethnicity, in the second trimester of pregnancy, was analysed by two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in order to identify biomarkers for DS.Results Gel comparison revealed nine proteins differentially expressed in maternal plasma in women with DS foetuses. Eight proteins, transthyretin (TTHY), ceruloplasmin (CERU), afamin (AFAM), alpha-1-microglobulin (AMBP), apolipoprotein E (APOE), serum amyloid P-component (SAMP), histidine-rich glycoprotein (HRG) and alpha-1-antitrypsin (A1AT) were up-regulated and one, clusterin (CLUS), down-regulated. All nine proteins are known to be involved in foetal growth and development. APOE, SAMP, AFAM and CLUS are associated with the DS phenotype. Western blot and densitometric analysis of APOE and SAMP confirmed the increase of both proteins by 19 and 48% respectively.Conclusions All differentially expressed proteins are candidate biomarkers for DS, providing opportunities for the development of non-invasive prenatal diagnosis. As these are preliminary findings, follow-up experiments are needed for their evaluation.

show abstract

“…The fine balance of these substances is recognized to play a significant role in supporting female fertility. Therefore, hFF represents a unique reservoir of potential biomarkers for the assessment of the oocyte and embryo quality of relevance for pregnancy outcome of in vitro fertilization (IVF) treatment [3]. …”

Section: Introductionmentioning

confidence: 99%

An Integrated Approach Based on Multiplexed Protein Array and iTRAQ Labeling for In-Depth Identification of Pathways Associated to IVF Outcome

et al. 2013

View full text Add to dashboard Cite

The emergence of high-throughput protein quantification methodologies has enabled the comprehensive characterization by longitudinal and cross-sectional studies of biological fluids under physiological and pathological conditions. In particular, the simultaneous investigation of cytokines and growth factors signaling pathways and their associated downstream effectors by integrated multiplexed approaches offers a powerful strategy to gain insights into biological networks and processes in living systems. A growing body of research indicates that bioactive molecules of human reproductive fluids, including human follicular fluid (hFF), may affect oocyte quality, fertilization and embryo development, thus potentially influencing the physiopathology of pregnancy-related conditions.In this work, an iTRAQ labeling strategy has been complemented with a multiplexed protein array approach to analyze hFFs with the aim to investigate biological processes and pathways related to in vitro fertilization (IVF) outcome. The iTRAQ labeling strategy lead to the quantification of 89 proteins, 30 of which were differentially expressed in hFFs with successful compared to unsuccessful IVF outcome. The targeted study, based on multiplexed antibody protein arrays, allowed the simultaneous quantification of 27 low abundance proteins, including growth factors, chemokines and cytokines endowed with pro- and anti-inflammatory activity. A significant number of differentially regulated proteins were involved in biological functions related to blood coagulation, acute phase response signaling and complement system. Overall, the present results provide an integrated overview of protein changes in hFFs associated to IVF outcome, thus improving current knowledge in reproductive medicine and fertility research.

show abstract

Proteomic analysis of human reproductive fluids

Cited by 8 publications

References 88 publications

Preliminary proteomic-based identification of a novel protein for Down's syndrome in maternal serum

Preliminary proteomic-based identification of a novel protein for Down's syndrome in maternal serum

Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma

An Integrated Approach Based on Multiplexed Protein Array and iTRAQ Labeling for In-Depth Identification of Pathways Associated to IVF Outcome

Contact Info

Product

Resources

About